Exagen Inc. (XGN) stock
XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)
Close on Nov 17, 2026Market cap $91.09MP/E –Yield –
Exagen cash
Cash and short-term investments held at the end of each period.
Exagen's cash was $24.59M at Jun 30, 2026. For fiscal 2025 it was $32.22M, up 44.9% from the year before. The highest annual figure on record is $99.54M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.22M | +44.9% |
| FY2024 | Dec 31, 2024 | $22.24M | -39.4% |
| FY2023 | Dec 31, 2023 | $36.69M | -41.4% |
| FY2022 | Dec 31, 2022 | $62.59M | -37.1% |
| FY2021 | Dec 31, 2021 | $99.54M | +73.0% |
| FY2020 | Dec 31, 2020 | $57.55M | -20.3% |
| FY2019 | Dec 31, 2019 | $72.18M | +444.2% |
| FY2018 | Dec 31, 2018 | $13.26M | +17.0% |
| FY2017 | Dec 31, 2017 | $11.34M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.59M | -18.7% |
| Q1 FY2026 | Mar 31, 2026 | $21.51M | +88.8% |
| Q4 FY2025 | Dec 31, 2025 | $32.22M | +44.9% |
| Q3 FY2025 | Sep 30, 2025 | $35.65M | +60.3% |
| Q2 FY2025 | Jun 30, 2025 | $30.23M | +22.5% |
| Q1 FY2025 | Mar 31, 2025 | $11.39M | -58.5% |
| Q4 FY2024 | Dec 31, 2024 | $22.24M | -39.4% |
| Q3 FY2024 | Sep 30, 2024 | $22.24M | -22.4% |
| Q2 FY2024 | Jun 30, 2024 | $24.68M | -22.1% |
| Q1 FY2024 | Mar 31, 2024 | $27.47M | -47.6% |
| Q4 FY2023 | Dec 31, 2023 | $36.69M | -41.4% |
| Q3 FY2023 | Sep 30, 2023 | $28.65M | -58.4% |
| Q2 FY2023 | Jun 30, 2023 | $31.67M | -58.6% |
| Q1 FY2023 | Mar 31, 2023 | $52.38M | -41.6% |
| Q4 FY2022 | Dec 31, 2022 | $62.59M | -37.1% |
| Q3 FY2022 | Sep 30, 2022 | $68.90M | -35.5% |
| Q2 FY2022 | Jun 30, 2022 | $76.49M | -32.1% |
| Q1 FY2022 | Mar 31, 2022 | $89.75M | -24.0% |
| Q4 FY2021 | Dec 31, 2021 | $99.54M | +73.0% |
| Q3 FY2021 | Sep 30, 2021 | $106.77M | +73.5% |
| Q2 FY2021 | Jun 30, 2021 | $112.68M | +76.6% |
| Q1 FY2021 | Mar 31, 2021 | $118.15M | +71.9% |
| Q4 FY2020 | Dec 31, 2020 | $57.55M | -20.3% |
| Q3 FY2020 | Sep 30, 2020 | $61.53M | -21.0% |
| Q2 FY2020 | Jun 30, 2020 | $63.80M | +290.5% |
| Q1 FY2020 | Mar 31, 2020 | $68.75M | +376.5% |
| Q4 FY2019 | Dec 31, 2019 | $72.18M | +444.2% |
| Q3 FY2019 | Sep 30, 2019 | $77.93M | +1322.0% |
| Q2 FY2019 | Jun 30, 2019 | $16.34M | +44.1% |
| Q1 FY2019 | Mar 31, 2019 | $14.43M | – |
| Q4 FY2018 | Dec 31, 2018 | $13.26M | – |
| Q3 FY2018 | Sep 30, 2018 | $5.48M | – |
| Q4 FY2017 | Dec 31, 2017 | $11.34M | – |
See a number that looks wrong?